NEW YORK (GenomeWeb News) – Biodesix said today that it has expanded a series E offering that raised $8.3 million in December.

The company added $6.1 million in a follow-on sale, bringing total proceeds from the sale of series E preferred shares to $14.4 million.

Existing shareholders of the company provided all funds. The offering will remain open to current shareholders until September of 2014.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.